10% Off
Jardian25 mg
Beximco Pharmaceuticals Ltd.
৳360.00
Add to cart
Empadus25 mg
Tablet
By
Best PriceTk /
1
Alternatives
Price
Medicine overview
Indications of Empadus 25 mg
Empadus 25 mg is indicated in:
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Theropeutic Class
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Pharmacology
Empadus 25 mg is a sodium glucose co-transporter-2 (SGLT-2) inhibitor.
Absorption
SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney.
Distribution
Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.
Excretion
The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion.
Dosage & Administration of Empadus 25 mg
The recommended dose of Empadus 25 mg is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empadus 25 mg, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empadus 25 mg is recommended.
Dosage of Empadus 25 mg
The recommended dose of Empadus 25 mg is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empadus 25 mg, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empadus 25 mg is recommended.
Interaction of Empadus 25 mg
Diuretics: Co-administration of Empadus 25 mg with diuretics resulted in increased urine volume. Insulin or Insulin Secretagogues: Co-administration of Empadus 25 mg with insulin or insulin secretagogues increases the risk for hypoglycemia. Positive Urine Glucose Test: Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control. Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.
Contraindications
Empadus 25 mg is contraindicated in patients with history of serious hypersensitivity reaction to Empadus 25 mg or any of its ingredients, severe renal impairment, end-stage renal disease, or dialysis.
Side Effects of Empadus 25 mg
The most common adverse reactions associated with Empadus 25 mg are urinary tract infections and female genital mycotic infections. Others common side effects includes dehydration, hypotension, weakness, dizziness and increased thirstiness.
Pregnancy & Lactation
There are no adequate and well-controlled studies of Empadus 25 mg in pregnant women. Empadus 25 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Empadus 25 mg is excreted in human milk. It is not recommended when breastfeeding.
Precautions & Warnings
Assessment of renal function is recommended prior to initiation of Empadus 25 mg and periodically thereafter. Empadus 25 mg should not initiated in patients with an eGFR less than 45 ml/min/1.73 m2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 ml/min/1.73 m2.
Overdose Effects of Empadus 25 mg
In the event of an overdose with Empadus 25 mg the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, perform clinical monitoring, and institute supportive treatment) should be employed. Removal of Empadus 25 mg by hemodialysis has not been studied.
Storage Conditions
Keep in a cool & dry place (below 30° C), protected from light & moisture. Keep out of the reach of children.
Drug Classes
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Mode Of Action
Empadus 25 mg is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.
Pregnancy
There are no adequate and well-controlled studies of Empadus 25 mg in pregnant women. Empadus 25 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Empadus 25 mg is excreted in human milk. It is not recommended when breastfeeding.
Frequently Asked Questions
What is Empadus 25 mg used for?
Empagliflozin is indicated in: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
What is the dosage of Empadus 25 mg?
The recommended dose of Empagliflozin is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empagliflozin, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empagliflozin is recommended.
What are the side effects of Empadus 25 mg?
The most common adverse reactions associated with Empagliflozin are urinary tract infections and female genital mycotic infections. Others common side effects includes dehydration, hypotension, weakness, dizziness and increased thirstiness.
Who should not take Empadus 25 mg?
Empagliflozin is contraindicated in patients with history of serious hypersensitivity reaction to Empagliflozin or any of its ingredients, severe renal impairment, end-stage renal disease, or dialysis.
What precautions should be taken with Empadus 25 mg?
Assessment of renal function is recommended prior to initiation of Empagliflozin and periodically thereafter. Empagliflozin should not initiated in patients with an eGFR less than 45 ml/min/1.73 m2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 ml/min/1.73 m2.
Is Empadus 25 mg safe during pregnancy and breastfeeding?
There are no adequate and well-controlled studies of Empagliflozin in pregnant women. Empagliflozin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Empagliflozin is excreted in human milk. It is not recommended when breastfeeding.
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.